Press Releases
GI Dynamics Announces the Presentation of Updated Data Sets at the 2022 Meeting of the American Diabetes Association
Data demonstrate favorable safety and efficacy profile for the duodenal jejunal bypass liner (DJBL) technology BOSTON — July 13, 2022 — GI Dynamics® Inc., a medical device company that is developing EndoBarrier® for patients with type 2 diabetes and obesity, is pleased to announce positive data...
read moreGI Dynamics Announces Final Data from the ENDO Trial, a Multicenter Study Demonstrating the Potential Use of EndoBarrier to Treat Type II Diabetes and Obesity.
Initial results show the duodenal jejunal bypass liner (DJBL) technology met overall glycemic control efficacy and SAE related device removal safety endpoints Findings Presented at DDW 2022 BOSTON – June 15, 2022 – GI Dynamics, a medical device company that is developing the EndoBarrier®...
read moreGI Dynamics Announces Approval of the I-STEP Clinical Study in India
Trial to focus on reduction of hemoglobin A1c for patients diagnosed with type 2 diabetes and obesity BOSTON & HYDERABAD, India–(BUSINESS WIRE)– GI Dynamics Inc., a medical device company that is developing the EndoBarrier® System for patients diagnosed with type 2 diabetes and...
read moreVideos
How EndoBarrier Works
EndoBarrier: Non-surgical Treatment for Patients with Type 2 Diabetes and …
Maintenance of Efficacy after EndoBarrier
UK First NHS EndoBarrier Service – Dr. Bob Ryder June …
BBC News Item
EndoBarrier treatment for diabetes & obesity following 1 year results …
